Boosting precision cancer testing for veterans with advanced prostate or lung cancer
Multilevel Veteran-centric Intervention to Improve Precision Oncology
NA · VA Office of Research and Development · NCT06825715
This program will try a three-part approach—short patient education, provider feedback, and an easier EMR ordering system—to increase molecular testing for veterans with advanced prostate or lung cancer at eight VA centers.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 2653 (estimated) |
| Sex | All |
| Sponsor | VA Office of Research and Development (fed) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06825715 on ClinicalTrials.gov |
What this trial studies
This mixed-methods type I hybrid effectiveness-implementation project rolls out a multilevel intervention at eight VA centers chosen for diversity in rurality, region, cancer volume, and care mode. The intervention combines a 5-minute patient educational video accessible by QR code, a 45-minute academic detailing session plus individualized audit-and-feedback for providers, and an EMR consult function that streamlines ordering and returning molecular test results. The investigators use the Theoretical Domains Framework and prior analyses to guide implementation and will collect validated survey measures from stakeholders. The primary outcome is the proportion of eligible veterans who receive guideline-recommended molecular testing, with mixed-methods evaluation of implementation processes and site-level changes.
Who should consider this trial
Good fit: Veterans with advanced prostate or lung cancer who are seen in oncology clinics at one of the participating VA medical centers are ideal candidates.
Not a fit: Patients whose cancer did not originate in the prostate or lung, or veterans who do not receive care at the participating VA sites, are not eligible and will not directly benefit from this intervention.
Why it matters
Potential benefit: If successful, more veterans could receive guideline-recommended molecular testing, improving access to targeted therapies and potentially improving survival and quality of life.
How similar studies have performed: Molecular testing and EMR-based ordering have improved care in prior work, and education plus audit-and-feedback have shown mixed but often positive effects, but combining all three components in a multilevel VA implementation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients in the VA with cancer of the lung or prostate who are seen in the oncology clinic Exclusion Criteria: * Cancer that did not originate in the prostate or the lung
Where this trial is running
New York, New York
- VA NY Harbor Healthcare System, New York, NY — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Daniel J Becker, MD — VA NY Harbor Healthcare System, New York, NY
- Study coordinator: Antoinette Vo, BA MA
- Email: antoinette.vo@va.gov
- Phone: (212) 686-7500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Cancers of the Prostate, Cancers of the Lung